Alamar Biosciences Management

Management criteria checks 3/4

Alamar Biosciences' CEO is Yuling Luo, appointed in May 2018, has a tenure of 8.08 years. total yearly compensation is $3.28M, comprised of 14.8% salary and 85.2% bonuses, including company stock and options. directly owns 6.88% of the company’s shares, worth $99.22M. The average tenure of the management team and the board of directors is 2.8 years and 4.2 years respectively.

Key information

Yuling Luo

Chief executive officer

US$3.3m

Total compensation

CEO salary percentage	14.76%
CEO tenure	8.1yrs
CEO ownership	6.9%
Management average tenure	2.8yrs
Board average tenure	4.2yrs

Recent management updates

No updates

Recent updates

Seeking Alpha • Apr 19

Alamar Biosciences: Looking For An Early Detection

Summary Alamar Biosciences surged 30% post-IPO, driven by enthusiasm for its precision proteomics technology targeting early disease detection. Alamar's revenue nearly tripled to $74M in 2025, with annualized sales multiples now around 12x; losses narrowed but remain substantial. Strong cash reserves and rapid topline growth offset concerns about ongoing losses and operating deleverage. I remain on the sidelines, closely monitoring future topline and bottom-line trends before considering a position. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Yuling Luo's remuneration changed compared to Alamar Biosciences's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2026	n/a	n/a	-US$43m
Dec 31 2025	US$3m	US$483k	-US$30m

Compensation vs Market: Yuling's total compensation ($USD3.28M) is below average for companies of similar size in the US market ($USD5.37M).

Compensation vs Earnings: Insufficient data to compare Yuling's compensation with company performance.

CEO

Yuling Luo (62 yo)

8.1yrs

Tenure

US$3,275,989

Compensation

Dr. Yuling Luo, Ph D., is a Venture Partner at Iif Management Company, LLC. He is Co-Founder and Director of Attovia Therapeutics, Inc. From August 2016 to February 2018, Dr. Luo served as President, Advan...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Yuling Luo	Co-Founder	8.1yrs	US$3.28m	6.88% $ 99.9m
Shiping Chen	Co-Founder	7.8yrs	US$1.58m	2.4% $ 34.8m
Justin McAnear	Chief Financial Officer	less than a year	US$1.94m	no data
Timothy White	President	less than a year	no data	no data
Yiyuan Yin	Founder	no data	no data	no data
Xiao-Jun Ma	Chief Technology Officer	5yrs	no data	no data
Stephen Williams	Chief Scientific Officer	less than a year	no data	no data
Alex Forrest-Hay	Senior Vice President of Sales	no data	no data	no data
Anna Berdine	Senior Vice President of Marketing	no data	no data	no data
Micah Litow	Senior VP of AI & Strategic Initiatives	no data	no data	no data

2.8yrs

Average Tenure

62yo

Average Age

Experienced Management: ALMR's management team is considered experienced (2.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Yuling Luo	Co-Founder	8.1yrs	US$3.28m	6.88% $ 99.9m
Shiping Chen	Co-Founder	6.1yrs	US$1.58m	2.4% $ 34.8m
Nicholas Naclerio	Independent Director	6.1yrs	no data	no data
Ian Ratcliffe	Independent Director	2.3yrs	no data	no data
Franklin Witney	Lead Independent Director	less than a year	no data	0% $ 0
Rebecca Chambers	Independent Director	less than a year	no data	no data

4.2yrs

Average Tenure

63.5yo

Average Age

Experienced Board: ALMR's board of directors are considered experienced (4.2 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/04 21:28
End of Day Share Price	2026/06/04 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alamar Biosciences, Inc. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Michael Ryskin	BofA Global Research
Casey Woodring	J.P. Morgan
Puneet Souda	Leerink Partners LLC